Happe Spine expects to receive FDA clearance within the next two to three months for its new porous, bioactive material that encourages bone growth, according to the report.
After FDA review, Happe plans to target hospitals, ASCs and orthopedic practices.
Last year, Happe closed on a $3.35 million series A funding round, and an additional $2 million round this year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
